YouTube Facebook LinkedIn Google+ Twitter Xinginstagram rss  

Big Growth, Innovation in Rare Disease Biotech

September 6, 2012 | Biotech innovation is thriving at Alexion Pharmaceuticals, a company focused on finding treatments that will transform the lives of patients with ultrarare diseases. The company's method has been a success. Alexion's growth has outpaced high rollers like Apple and with shares up 600% since the approval of Soliris for a rare cause of anemia. Forbes
Click here to login and leave a comment.  


Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact Angela Parsons, 781.972.5467.